EUVIMEDEUVIMED entdecken
Open Access

Heterophyllin B enhances the benefits of intermittent fasting in the treatment of metabolic dysfunction‑associated steatotic liver disease via activation of GLP‑1R

Kaimin Li, Ligong Deng, Lijun Xue, Shukun Yao

International Journal of Molecular Medicine · 2025

DOI: 10.3892/ijmm.2025.5641 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Medicine, 2025. Verfasst von Kaimin Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Biological and Medical Engineering, Beijing University of Aeronautics and Astronautics, Beijing 100191, P.R. China. Hauptthemen laut MEDLINE: Fasting, Glucagon-Like Peptide-1 Receptor, Peptides, Cyclic, Fatty Liver. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Intermittent fasting (IF) has shown particularly promising short‑term effects in improving metabolic dysfunction‑associated steatotic liver disease (MASLD), although its long‑term efficacy remains unclear. Heterophyllin B (HP‑B), a cyclopeptide compound derived from Pseudostellaria heterophylla, is known for its potent anti‑inflammatory and hypoglycemic properties. However, studies investigating the potential role of HP‑B in the management of MASLD are lacking. In vitro, an OA/PA‑induced lipid accumulation model was established using HepG2/Huh‑7 cells. The therapeutic effects of HP‑B and fasting‑mimicking conditions were evaluated through Cell Counting Kit‑8 assay, Oil Red O staining, reverse transcription‑quantitative PCR, and western blot analysis. For in vivo studies, C57BL/6J mice were fed a high‑fat diet and treated with HP‑B, IF, or their combination. Mechanistic validation was performed via adenovirus‑mediated GLP‑1R knockdown. The present study aimed to explore whether HP‑B can serve as an adjunctive supplement to enhance the benefits of IF in the treatment of MASLD. HepG2 and Huh‑7 liver cancer cells treated with oleic acid/palmitic acid (OA/PA) presented significant lipid accumulation, which was attenuated by HP‑B treatment and fasting. The combination treatment markedly reduced lipid levels and oxidative stress, as well as restored the mitochondrial membrane potential, with a synergistic effect over treatment alone. In addition, the combination of HP‑B and fasting upregulated glucagon‑like peptide‑1 receptor (GLP‑1R) and peroxisome proliferator‑activated receptor gamma coactivator 1‑alpha expression, reversing the OA/PA‑induced decline. In high‑fat diet‑fed mice, the combination treatment reduced hepatic lipid accumulation, decreased liver weight, decreased mouse body weight, and improved biochemical indices of liver function. The beneficial effects of HP‑B and fasting were reversed after silencing GLP‑1R with small interfering RNA or Ad‑GLP‑1R, emphasizing the critical role of GLP‑1R in mediating these protective effects. In conclusion, the synergistic effects of HP‑B and fasting on improving lipid metabolism and mitochondrial function are mediated primarily through the regulation of GLP‑1R, making it a promising therapeutic target for the treatment of MASLD and other lipid metabolism‑related disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FastingGlucagon-Like Peptide-1 ReceptorPeptides, CyclicFatty LiverAnimalsHumansMiceMice, Inbred C57BLHep G2 CellsMaleLipid MetabolismDiet, High-FatLiverIntermittent Fasting

Stichwörter der Autor:innen

glucagon‑like peptide‑1 receptorheterophyllin Bintermittent fastingmetabolic dysfunction‑associated steatotic liver diseaseperoxisome proliferator‑activated receptor gamma coactivator 1‑alpha

Substanzen

Glucagon-Like Peptide-1 ReceptorPeptides, Cyclic

Autor:innen und Institutionen

  • School of Biological and Medical Engineering, Beijing University of Aeronautics and Astronautics, Beijing 100191, P.R. China.
  • Department of Gastroenterology, Jinan Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250013, P.R. China.

Zitieren

APA

Li, K., Deng, L., Xue, L., & Yao, S. (2025). Heterophyllin B enhances the benefits of intermittent fasting in the treatment of metabolic dysfunction‑associated steatotic liver disease via activation of GLP‑1R. International Journal of Molecular Medicine. https://doi.org/10.3892/ijmm.2025.5641

Vancouver

Li K, Deng L, Xue L, Yao S. Heterophyllin B enhances the benefits of intermittent fasting in the treatment of metabolic dysfunction‑associated steatotic liver disease via activation of GLP‑1R. International Journal of Molecular Medicine. 2025. doi:10.3892/ijmm.2025.5641

BibTeX
@article{Li2025,
  author = {Li, Kaimin and Deng, Ligong and Xue, Lijun and Yao, Shukun},
  title = {Heterophyllin B enhances the benefits of intermittent fasting in the treatment of metabolic dysfunction‑associated steatotic liver disease via activation of GLP‑1R},
  journal = {International Journal of Molecular Medicine},
  year = {2025},
  doi = {10.3892/ijmm.2025.5641}
}
Kostenlos starten →